Immix Biopharma, Inc.
IMMX
$10.97
$0.050.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 159.48% | 78.12% | 43.00% | 4.37% | 10.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.43% | 130.71% | 118.43% | 3.62% | 42.85% |
| Operating Income | -85.43% | -130.71% | -118.43% | -3.62% | -42.85% |
| Income Before Tax | -74.53% | -122.53% | -122.37% | -6.16% | -50.46% |
| Income Tax Expenses | 60.67% | -- | 4.63% | -30.63% | -13.59% |
| Earnings from Continuing Operations | -74.51% | -122.05% | -122.10% | -6.10% | -50.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.51% | -122.05% | -122.10% | -6.10% | -50.76% |
| EBIT | -85.43% | -130.71% | -118.43% | -3.62% | -42.85% |
| EBITDA | -85.69% | -130.63% | -118.29% | -2.38% | -41.73% |
| EPS Basic | 17.97% | -19.16% | -63.21% | 2.22% | -44.76% |
| Normalized Basic EPS | 17.98% | -19.39% | -63.45% | 2.18% | -45.16% |
| EPS Diluted | 17.97% | -19.16% | -63.21% | 2.22% | -44.76% |
| Normalized Diluted EPS | 17.98% | -19.39% | -63.45% | 2.18% | -45.16% |
| Average Basic Shares Outstanding | 112.69% | 86.42% | 36.06% | 8.50% | 4.16% |
| Average Diluted Shares Outstanding | 112.69% | 86.42% | 36.06% | 8.50% | 4.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |